Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MTOR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MTOR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MTOR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MTOR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005134610 | Endometrium | AEH | negative regulation of hydrolase activity | 65/2100 | 379/18723 | 3.18e-04 | 3.57e-03 | 65 |
GO:00096159 | Endometrium | AEH | response to virus | 63/2100 | 367/18723 | 3.81e-04 | 4.10e-03 | 63 |
GO:00107616 | Endometrium | AEH | fibroblast migration | 14/2100 | 47/18723 | 4.51e-04 | 4.76e-03 | 14 |
GO:00011017 | Endometrium | AEH | response to acid chemical | 28/2100 | 135/18723 | 9.24e-04 | 8.43e-03 | 28 |
GO:00433889 | Endometrium | AEH | positive regulation of DNA binding | 15/2100 | 56/18723 | 9.88e-04 | 8.90e-03 | 15 |
GO:00432005 | Endometrium | AEH | response to amino acid | 24/2100 | 116/18723 | 2.14e-03 | 1.65e-02 | 24 |
GO:00510905 | Endometrium | AEH | regulation of DNA-binding transcription factor activity | 69/2100 | 440/18723 | 2.51e-03 | 1.87e-02 | 69 |
GO:00726656 | Endometrium | AEH | protein localization to vacuole | 16/2100 | 67/18723 | 2.52e-03 | 1.87e-02 | 16 |
GO:00712302 | Endometrium | AEH | cellular response to amino acid stimulus | 16/2100 | 71/18723 | 4.68e-03 | 2.99e-02 | 16 |
GO:00018198 | Endometrium | AEH | positive regulation of cytokine production | 71/2100 | 467/18723 | 4.76e-03 | 3.02e-02 | 71 |
GO:00192165 | Endometrium | AEH | regulation of lipid metabolic process | 53/2100 | 331/18723 | 4.86e-03 | 3.07e-02 | 53 |
GO:00712293 | Endometrium | AEH | cellular response to acid chemical | 17/2100 | 80/18723 | 6.76e-03 | 3.94e-02 | 17 |
GO:001046610 | Endometrium | AEH | negative regulation of peptidase activity | 43/2100 | 262/18723 | 6.78e-03 | 3.95e-02 | 43 |
GO:001603217 | Endometrium | EEC | viral process | 112/2168 | 415/18723 | 2.48e-18 | 1.35e-15 | 112 |
GO:001905817 | Endometrium | EEC | viral life cycle | 86/2168 | 317/18723 | 1.63e-14 | 4.65e-12 | 86 |
GO:001907917 | Endometrium | EEC | viral genome replication | 42/2168 | 131/18723 | 3.43e-10 | 3.61e-08 | 42 |
GO:005109817 | Endometrium | EEC | regulation of binding | 83/2168 | 363/18723 | 6.72e-10 | 6.61e-08 | 83 |
GO:190382917 | Endometrium | EEC | positive regulation of cellular protein localization | 67/2168 | 276/18723 | 2.27e-09 | 1.84e-07 | 67 |
GO:001604915 | Endometrium | EEC | cell growth | 95/2168 | 482/18723 | 1.16e-07 | 5.54e-06 | 95 |
GO:015011614 | Endometrium | EEC | regulation of cell-substrate junction organization | 25/2168 | 71/18723 | 1.63e-07 | 7.54e-06 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTOR | SNV | Missense_Mutation | novel | c.7184A>G | p.Asn2395Ser | p.N2395S | P42345 | protein_coding | tolerated(1) | possibly_damaging(0.703) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MTOR | SNV | Missense_Mutation | | c.7498N>T | p.Ile2500Phe | p.I2500F | P42345 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MTOR | SNV | Missense_Mutation | rs769877976 | c.25G>A | p.Ala9Thr | p.A9T | P42345 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.835) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MTOR | SNV | Missense_Mutation | novel | c.6287N>T | p.Asp2096Val | p.D2096V | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.3142A>C | p.Ile1048Leu | p.I1048L | P42345 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.5276N>G | p.Leu1759Arg | p.L1759R | P42345 | protein_coding | tolerated(0.51) | probably_damaging(0.995) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
MTOR | SNV | Missense_Mutation | | c.397N>G | p.Leu133Val | p.L133V | P42345 | protein_coding | deleterious(0) | possibly_damaging(0.563) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MTOR | SNV | Missense_Mutation | | c.4835N>C | p.Arg1612Pro | p.R1612P | P42345 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
MTOR | SNV | Missense_Mutation | novel | c.3722N>G | p.Gln1241Arg | p.Q1241R | P42345 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | | c.7162N>C | p.Glu2388Gln | p.E2388Q | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | QUINACRINE | QUINACRINE | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | BEZ235 | DACTOLISIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | TCMDC-125575 | CHEMBL587620 | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | PERPHENAZINE | PERPHENAZINE | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | PAZOPANIB | PAZOPANIB | 24625776 |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | 249565693 | | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | CAFFEIC ACID PHENETHYL ESTER | CAFFEIC ACID PHENETHYL ESTER | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | AZD2014 | VISTUSERTIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | GDC-0980/RG7422 | | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | EVEROLIMUS | EVEROLIMUS | 24625776,25295501 |